Please ensure Javascript is enabled for purposes of website accessibility

Top 3 Healthcare Stocks to Buy Right Now

By Mark Prvulovic - Updated Apr 2, 2020 at 7:14AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

With the coronavirus pandemic pushing stock prices to historic lows, there are plenty of promising companies to invest in today.

Now might be one of the best times to invest in healthcare stocks. As COVID-19 continues to spread throughout the world, many companies have already seen significant increases in revenue as demand for their services grows.

While there's plenty of companies to choose from, you still need to do your due diligence before making an investment decision. Here are three healthcare stocks that check all the boxes for a sound investment and are worth checking out.

A growing stack of coins on top of wooden blocks that spell out the word health.

Image source: Getty Images.

1. Teladoc

Telehealth services have understandably become hot stocks amid this COVID-19 pandemic. With the Trump administration dialing back previous telehealth restrictions, many companies have seen a dramatic surge in new patient appointments.

Teladoc (TDOC 6.13%) is one of the primary telehealth service providers, and shares of the stock shot up considerably over the past month. In early March, Teladoc said it saw a 50% increase in new patient visits, largely due to COVID-19. At the time, the total number of U.S. cases was still relatively small, with around 500 confirmed COVID-19 infections. In under a month, this figure has ballooned to over 150,000, with some experts warning that there could be millions of cases in the near future.

As such, demand for Teladoc is expected to continue to increase exponentially. However, even without COVID-19, Teladoc has been reporting stellar growth figures. Fourth-quarter revenues increased to $156.5 million, a 27% increase from last year, while the total number of visits increased by 44% to 1.2 million. All in all, the future looks especially bright for this company, something that many growth investors are quickly realizing.

2. Bristol Myers Squibb

Value and dividend-focused investors also have many investment opportunities in the healthcare sector. In particular, a number of large-cap pharmaceutical giants are reporting double-digit percentage growth figures, while paying out impressive dividends. Bristol Myers Squibb (BMY 1.49%) is one such company.

Despite reporting a 15.4% increase in revenue between the fourth quarter of 2018 and the fourth quarter of 2019, as well as boasting a solid 3.4% dividend yield, this company trades at a pretty cheap valuation. Its price-to-sales (P/S) ratio comes in at 3.6, while its price-to-equity (P/E) ratio is 24.8.

Bristol's existing lineup of drugs is already doing quite well, including two of its best-performing drugs, cancer treatment Eliquis and an anticoagulant called Opdivo, which brought in $7.9 billion and $7.2 billion in annual revenue, respectively. Both drugs are reporting impressive revenue growth, with Eliquis seeing a 23% increase in sales while Opdivo had a 7% increase from last year.

The company's acquisition of Celgene in 2019 added a number of potential blockbusters to its clinical lineup. The biggest of these is Revlimid, a treatment for a type of bone marrow cancer known as multiple myeloma. In just a one-month period between November and December, Revlimid brought in $1.3 billion in revenue. Given a full year's worth of sales, Revlimid could easily become Bristol's top revenue-generating product.

Although some investors might scoff at Bristol's relatively high debt level -- around $46.7 billion, thanks to its Celgene acquisition -- the rest of the business is extremely sound. With a competent management team, double-digit revenue growth, and a solid dividend, Bristol Myers Squibb looks very well poised to have a stellar 2020.

3. Gilead Sciences

If you're looking to invest in a company that's directly working on a COVID-19 treatment, then you have a lot of different stocks to choose from. Both small-cap biotech companies and well-established healthcare giants have jumped into this area, quickly making it quite a competitive arena.

Gilead Sciences (GILD 0.82%) stands out in this regard thanks to its head start on its own COVID-19 treatment, remdesivir. A former Ebola drug, remdesivir is an antiviral treatment that has shown some effectiveness in treating symptoms of patients with the novel coronavirus. Although a more recent study featuring 12 patients found the efficacy of remdesivir to be somewhat unclear, Gilead's CEO said further details about multiple ongoing studies will be available in the coming weeks.

Even putting remdesivir aside, Gilead still has a lot going for it. For one, the company remains a leader in the HIV market, with its HIV business segment bringing in $4.6 billion in fourth-quarter revenue, up 12.2% from the fourth quarter of 2018. Its prevention pill Truvada remains a strong revenue driver for the company, alongside other HIV drugs such as Biktarvy, which has seen annual sales almost quadruple between 2018 and 2019.

All this is on top of an already attractive 3.7% dividend yield, which is quite respectable for any company. There's a lot to be excited about with Gilead, regardless of how its COVID-19 treatment works out, and investors should feel confident that this company will do well in the months and years to come.

Mark Prvulovic has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Bristol Myers Squibb, Gilead Sciences, and Teladoc Health. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Bristol Myers Squibb Company Stock Quote
Bristol Myers Squibb Company
$75.57 (1.49%) $1.11
Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
$62.96 (0.82%) $0.51
Teladoc Health, Inc. Stock Quote
Teladoc Health, Inc.
$40.32 (6.13%) $2.33

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/13/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.